Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | ARF6 | P62330 | 4/20 | 0.38 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 5/20 | 0.35 |
| ▸ | F9 | P00740 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275442 | 0.87 | ARF6 (0.41) | CNR1ARF6PSDKDM4EHTT | |
| SCHEMBL10313475 | 0.83 | ALPL (0.41) | CNR1KDM5BPTGS1PTGS2PDE3B | |
| SCHEMBL10276231 | 0.82 | CNR1 (0.41) | CNR1KDM5B | |
| SCHEMBL10276296 | 0.80 | PSD (0.52) | ARF6PSDKDM4EHTTCRHR1 | |
| SCHEMBL10313476 | 0.80 | CRHR1 (0.39) | KDM4ECRHR1 | |
| SCHEMBL10275893 | 0.79 | CYP3A4 (0.41) | ARF6PSDKDM4ECRHR1 | |
| SCHEMBL12826181 | 0.76 | CRHR1 (0.44) | KDM4ECRHR1HSD11B1 | |
| SCHEMBL10275250 | 0.75 | ARF6 (0.42) | CNR1ARF6 | |
| SCHEMBL10275199 | 0.74 | ARF6 (0.36) | CNR1ARF6PSDKDM5BPTGS1 | |
| SCHEMBL13515966 | 0.74 | MAPT (0.46) | KDM4EHTTCRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011035518-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | 辽宁利锋科技开发有限公司 (CN) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | CNR1 877/4885ARF6 3355/4885PSD 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.